ReviewBMC pediatrics2025
Severe combined immunodeficiency with BCG-osis by salvage therapy with allogeneic hematopoietic stem cell transplantation: cases report and literature review.
Review in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere combined immunodeficiency(SCID) combined with Bacillus Calmette-Guérin(BCG) disease(BCG-osis) is a rare but life-threatening complication in pediatric patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early recognition and intervention are essential to prevent severe complications. CASE PRESENTATION: We have described two pediatric cases of SCID combined with BCG-osis in which the patients received salvage therapy with allo-HSCT. Data were collected from two male infants who underwent allo-HSCT for SCID with BCG-osis at Wuhan Children’s Hospital between January 2017 and December 2022. The data of the two patients were retrospectively collected and analyzed to summarize their clinical characteristics, treatment, and prognosis. Patient 1 presented with SCID combined with disseminated BCG-osis and underwent HSCT after only 30 days of anti-tuberculosis therapy. The tuberculosis infection recurred at 83 days after transplantation, and the patient eventually died of multi-organ failure and disseminated intravascular coagulation. Patient 2 presented with SCID combined with disseminated BCG-osis after HSCT. The patient responded well to antituberculosis drugs and successfully completed a year and a half of anti-tuberculosis treatment. On day 591 post-transplant, the anti-tuberculosis regimen was discontinued in this patient.
conclusionsPatients with SCID have severe defects in cellular and humoral immunity. Genetic screening at birth would help identify such patients, and the BCG vaccination should be delayed in such cases. The sole curative option for SCID is HSCT, which can achieve immune reconstitution when performed early on and can improve the survival rate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.